Last reviewed · How we verify
Vigadexa®
At a glance
| Generic name | Vigadexa® |
|---|---|
| Also known as | Moxifloxacin Hydrochloride 5mg/mL + Dexamethasone Disodium Phosphate 1mg/mL |
| Sponsor | EMS |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification (PHASE2)
- Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vigadexa® CI brief — competitive landscape report
- Vigadexa® updates RSS · CI watch RSS
- EMS portfolio CI